VYNE Therapeutics, focused on small molecule BET inhibitors for immune-mediated inflammatory diseases, faced clinical challenges leading to halted trials and an FDA clinical hold. The company sold its legacy MST Franchise in 2022 and initiated a strategic review in 2025, culminating in a planned merger with Yarrow Biosciences that will redefine its business focus. Despite operating remotely and maintaining strong liquidity with no debt, VYNE’s near-term prospects hinge on the success of this merger and potential monetization of existing assets.